Skip to main content
Clinical Trials/NCT00726362
NCT00726362CompletedNot Applicable

To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia

AstraZeneca1 site in 1 country3,270 target enrollmentStarted: December 2007Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
3,270
Locations
1
Primary Endpoint
Changes on LDL-C, HDL-C, TG, TC

Study Overview

Brief Summary

The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under local clinical practice in treating patients with hyperlipidemia. Surveillance data (Lipid Profile) will be collected during course of usual clinical practice or captured upon its availability.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • patients diagnosed with hyperlipidemia
  • Patients who are just starting a statin treatment, who need to switch from current therapy to a statin medication, or who are receiving dosage adjustment of statin as judged by the physicians
  • Patients who are willing to participate in this study and who sign an informed consent form

Exclusion Criteria

  • Pregnancy or breast feeding
  • Patient are illiterate or unable to fill the questionnaire for any reason
  • Patients with contraindications to the use of certain statins as needed prescribed by physicians (as per commercially available statins package insert) including the use of rosuvastatin.
  • Any clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications

Outcomes

Primary Outcomes

Changes on LDL-C, HDL-C, TG, TC

Time Frame: 3~6 months

Secondary Outcomes

  • ratio for treatment-to-goal(3~6 months)
  • drug compliance(3~6 months)
  • correlation between patient's insight and therapeutic outcome(3~6 months)

Investigators

Sponsor Class
Industry

Study Sites (1)

Loading locations...

Similar Trials